SMRMIF007U Course in Biopharmaceuticals – Quality Development and Documentation
This course is offered in collaboration between University of Copenhagen and Medicademy as part of the Master of Medicines Regulatory Affairs. It is possible to follow the course as a single course student.
The aim of this course is to give attendees knowledge about the scientific background of biotechnological products and the regulatory requirements to fulfil, in order to obtain approval of these types of medicinal products.
Attendees will get an understanding of the quality issues specific to biopharmaceuticals, for example; the generation of a recombinant microorganism, the expression of the product from the microorganisms and its purification, and the regulatory expectations for characterisation of a biopharmaceutical product and to release/stability specifications set for these types of products. As process changes are inevitable during development of a biological/biotechnological product this course will provide the implications of changes in the production process and elaborate the concept of comparability.
In addition to providing the students with a general understanding of specific quality issues for biopharmaceuticals, this course will focus on how to prepare regulatory CMC/Quality strategies and how to ensure compliance with regulatory requirements throughout the clinical development and post-approval processes. The discussions on CMC/Quality strategies will include both EU and FDA aspects, and the lectures will focus attention on both EU and FDA regulatory procedures for approval of biopharmaceuticals. Further, the course will guide the students through the structure of CMC/Quality sections for IND/CTA and BLA/MAA in the CTD format.
The course is connected to the exam SMRMIF007E Exam in Biopharmaceuticals - Quality Development and Documentation. To earn full 4 credits you are required to pass the exam.
After completing the course the student is expected to be able to:
Knowledge
Understand the basic principles of manufacturing biopharmaceuticals - from the recombinant starting material to the final product, including product characterization and setting specifications as well as the specific quality issues of biopharmaceuticals.
Understand the critical parts of CMC/Quality sections of the submission file.
Understand the regulatory expectations to meet in CMC/Quality documentation throughout the different phases of clinical development for approval of these types of medicinal products and for demonstration comparability during life cycle management.
Skills
Evaluate and organise information provided by CMC/Quality stakeholders during product development and post-approval.
Prepare regulatory CMC/Quality strategies, consider both FDA and EU aspects throughout the clinical development.
Evaluate relevant regulations and guidelines for biopharmaceuticals.
Competencies
Apply best practice in product characterisation and setting of release/stability specifications of a biopharmaceutical, including comparability issues related to manufacturing changes, when preparing a CMC/Quality meeting with Authorities, and when structuring the CMC/Quality sections for IND/CTA and BLA/MAA in the CTD format.
The syllabus comprises selected CHMP/ICH guidelines and EC directives and regulations. A list of reading material will be distributed electronically approx. 4 weeks before the course. The course participants are expected to study parts of the syllabus before the course, especially the ICH Q4M: M4Q Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality - Module 2: Quality Overall Summary, Module 3: Quality. In total corresponding to approximately 1400 pages.
• A relevant bachelor degree or equivalent
• A minimum of 2 years working experience within regulatory affairs
• Proficiency in English
- Category
- Hours
- Lectures
- 22
- Preparation
- 54
- Theory exercises
- 5
- Total
- 81
- Credit
- 3 ECTS
- Type of assessment
- Course participationParticipation in the course is a requirement for participating in the exam SMRMIF003E Exam in Clinical Development – Efficacy of Medicines
- Marking scale
- passed/not passed
- Censorship form
- No external censorship
Criteria for exam assesment
To achieve the grade passed the student shall (in an adequate level) be able to:
Knowledge
Understand the basic principles of manufacturing biopharmaceuticals - from the recombinant starting material to the final product, including product characterization and setting specifications as well as the specific quality issues of biopharmaceuticals.
Understand the critical parts of CMC/Quality sections of the submission file.
Understand the regulatory expectations to meet in CMC/Quality documentation throughout the different phases of clinical development for approval of these types of medicinal products and for demonstration comparability during life cycle management.
Skills
Evaluate and organise information provided by CMC/Quality stakeholders during product development and post-approval.
Prepare regulatory CMC/Quality strategies, consider both EU and FDA aspects throughout the clinical development.
Evaluate relevant regulations and guidelines for biopharmaceuticals.
Competencies
- Apply best practice in product characterisation and setting of release/stability specifications of a biopharmaceutical, including comparability issues related to manufacturing changes, when preparing a CMC/Quality meeting with Authorities, and when structuring the CMC/Quality sections for IND/CTA and BLA/MAA in the CTD format.
Course information
- Language
- English
- Course code
- SMRMIF007U
- Credit
- 3 ECTS
- Level
- Part Time Master
- Duration
- Placement
- Autumn
November 8 - 10 2017
- Schedule
- .
- Continuing and further education
- Price
Prices vary according to type of enrolment and nationality. For details please visit:
Fee includes course materials and meals during the days and a networking dinner the first evening. If textbooks are required, it must be purchased by the participants
- Study board
- Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
Contracting department
- Department of Pharmacy
Course Coordinators
- Lene Jørgensen
(14-6f687168316d72756a68717668714376787167316e7831676e)
Head of studies
Louise Ploug Berth, RA CMC Specialist, RA Inflammation Projects, Novo Nordisk A/S, Denmark (chief responsibility)
Sandra Patricia Auguste-Bowler, Scientific Adviser (Pharmaceutical Expert), LEO Pharma A/S, Denmark